Herpesvirus Antiviral Resistance
Database


    • TOP

    UL97

    Mutations:

    Mutant Antiviral EC50 ratio Phenotype Assay Reference
    Q19E Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    Q54E Details
    N68D Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    N108S Natural polymorphism Details
    S108N Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    D118N Details
    L126Q Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    D184G Details
    G215A Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    I244V Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    P247S Natural polymorphism Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    F294C Natural polymorphism Details
    K316T Natural polymorphism Details
    E317A Natural polymorphism Details
    D329H 1.00 No resistance Details Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    L337M Maribavir 3.40 Intermediate level resistance Details Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
    L337M Ganciclovir 1.02 No resistance Details Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo. (Aug 2012)
    F342S Maribavir 18.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    F342S Ganciclovir 7.80 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    F342Y Maribavir 4.70 Intermediate level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    F342Y Ganciclovir 6.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    V353A Maribavir 10.00 High level resistance Details Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
    V353A Ganciclovir 1.00 No resistance Details Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. (Jul 2007)
    K355del Maribavir 304.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    K355del Ganciclovir 16.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356G Maribavir 108.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356G Ganciclovir 5.50 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V356W Natural polymorphism Details
    V356L Natural polymorphism Details
    K356V Details
    K359E Ganciclovir 4.00 Intermediate level resistance Details Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
    K359Q Ganciclovir 4.00 Intermediate level resistance Details Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infection. (Dec 2019)
    L397R Maribavir 390.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L397R Ganciclovir 2.30 Low level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L405P Ganciclovir 2.70 Low level resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    T409M Ganciclovir 1.30 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    T409M Maribavir 80.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411L Maribavir 21.00-99.00 Range of values of High level resistance Details Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411L Ganciclovir 0.70 No resistance Details Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411N Maribavir 9.00 High level resistance Details Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411N Ganciclovir 0.71 No resistance Details Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. (Jan 2008)
    H411Y Maribavir 17.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H411Y Ganciclovir 0.50 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A427V Ganciclovir 0.95 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    T429I Natural polymorphism Details
    Q449K Details Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. (Oct 2001)
    D456N Maribavir 278.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    D456N Ganciclovir 12.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    M460I Filociclovir 12.00 High level resistance Details Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    M460I Maribavir 0.21 Possible hypersensitivity, no resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460I Ganciclovir 12.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460T Ganciclovir 9.30 High level resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    M460V Filociclovir 4.00 Intermediate level resistance Details Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    M460V Maribavir 0.30 Possible hypersensitivity, no resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460V Ganciclovir 9.10 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    M460L Details
    V466G Maribavir 321.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    V466G Ganciclovir 11.00 High level resistance Details Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis. (Apr 2010)
    V466M Ganciclovir 1.30 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    V466M Maribavir Details
    H469Y Ganciclovir 1.00 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    R476C Ganciclovir Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    A478V Ganciclovir 0.85 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    C480F Maribavir 210.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C480F Ganciclovir 2.30 Low level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C480R Maribavir 243.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    C480R Ganciclovir 9.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    N510S 1.20 No resistance Details Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. (Aug 1998)
    C518Y Ganciclovir 12.00 High level resistance Details Rapid detection of human cytomegalovirus UL97 and UL54 mutations for antiviral resistance in clinical specimens. (May 2013)
    H520Q Filociclovir 5.00-20.00 Range of values of High level resistance Details Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility. (Jan 2011)
    H520Q Maribavir 0.66 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    H520Q Ganciclovir 9.70 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    P521L Maribavir 428.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    P521L Ganciclovir 17.00 High level resistance Details Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance. (Jul 2013)
    M550I 8-cyclopentyl-1,3-dipropylxanthine 0.85 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    G561A 1.00 No resistance Details Antiviral drug resistance of human cytomegalovirus. (Oct 2010)
    A582V 8-cyclopentyl-1,3-dipropylxanthine 0.82 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    H587Y Acyclovir Details
    A588V 5-fluorouracil 1.15 No resistance Details Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance. (Jun 2010)
    590-600del Ganciclovir 6.30 High level resistance Details Emergence of multiple human cytomegalovirus ganciclovir-resistant mutants with deletions and substitutions within the UL97 gene in a patient with severe combined immunodeficiency. (Feb 2001)
    590-603del Ganciclovir Details Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. (Aug 1999)
    591-594del Ganciclovir 6.00 High level resistance Details A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. (Sep 1992)
    A591D Diazoxide Details
    A591V Ganciclovir 1.30 No resistance Details Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. (Nov 2000)
    591-607del Ganciclovir 6.20 High level resistance Details Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    C592F Ganciclovir 31.50 High level resistance Details Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. (Sep 2001)
    C592G Filociclovir 2.20-4.90 Range of values between Low level resistance and Intermediate level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C592G Maribavir 0.78 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C592G Ganciclovir 3.20 Intermediate level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594E Ganciclovir 3.00 Intermediate level resistance Details Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    A594G Ganciclovir 13.50 High level resistance Details Value of a ligase chain reaction assay for detection of ganciclovir resistance-related mutation 594 in UL97 gene of human cytomegalovirus. (Sep 1997)
    A594P Ganciclovir 7.90 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594P Maribavir 1.60 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594S Ganciclovir 2.20-4.90 Range of values between Low level resistance and Intermediate level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    A594T Ganciclovir 5.00 High level resistance Details Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
    A594T Maribavir 0.73 No resistance Details Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. (May 1997)
    A594V Filociclovir 2.20-4.90 Range of values between Low level resistance and Intermediate level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    A594V Maribavir 1.90 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    A594V Ganciclovir 6.90 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595F Maribavir 1.30 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595F Ganciclovir 6.20 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S Filociclovir <2.20 No more than Low level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    L595S Maribavir 1.30 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595S Ganciclovir 7.50 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595W Maribavir 1.20 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595W Ganciclovir 9.00 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    L595del Ganciclovir 13.30 High level resistance Details A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. (Feb 1995)
    595-603del Ganciclovir 8.40 High level resistance Details Novel mutation in the CMV UL97 gene associated with resistance to ganciclovir therapy. (Mar 1999)
    E596del Ganciclovir Details Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009)
    E596G Ganciclovir 2.30 Low level resistance Details Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. (Jan 2002)
    E596Y Ganciclovir 6.40 High level resistance Details Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015)
    E596Q Ganciclovir 2.70 Low level resistance Details Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024)
    N597del Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    597-598del Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    597-599del Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    G598S Ganciclovir Details Emergence of a ganciclovir-resistant human cytomegalovirus strain with a new UL97 mutation in an AIDS patient. (May 1998)
    599-603del Ganciclovir 5.30 High level resistance Details Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998)
    K599E Ganciclovir Details Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. ( 2009)
    K599R Ganciclovir 1.10 No resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    K599T Ganciclovir 5.30 High level resistance Details Genetic analysis of a ganciclovir-resistant human cytomegalovirus mutant. (Dec 1998)
    L600I Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    L600del Ganciclovir 1.90 No resistance Details Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. (Nov 2001)
    T601M Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    601-602del Ganciclovir 11.00 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    601-603del Ganciclovir 11.00 High level resistance Details Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
    C603R Ganciclovir Details Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. (Sep 2002)
    C603S Ganciclovir 1.90 No resistance Details Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. (Sep 2002)
    C603W Filociclovir 2.20-4.90 Range of values between Low level resistance and Intermediate level resistance Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C603W Maribavir 1.20 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603W Ganciclovir 5.90 High level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603Y Maribavir 0.89 No resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    C603Y Ganciclovir 2.80 Low level resistance Details Ganciclovir and maribavir cross-resistance revisited: Relative drug susceptibilities of canonical cytomegalovirus mutants. (Feb 2024)
    D605E Ganciclovir Details Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. (Apr 2020)
    C607F Ganciclovir 1.90 No resistance Details Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001)
    C607Y Ganciclovir 12.50 High level resistance Details Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. (Dec 2001)
    I610T Ganciclovir 2.60 Low level resistance Details Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. ( 2015)
    A613V Ganciclovir 2.30 Low level resistance Details Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation. (Dec 2013)
    Y617H 8-cyclopentyl-1,3-dipropylxanthine 0.84 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)
    Y617del Maribavir 372.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    Y617del Ganciclovir 10.00 High level resistance Details Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions. ( 2014)
    G623S Details
    A639T Natural polymorphism Details
    E655K Ganciclovir 1.70 No resistance Details Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping. (Nov 2014)
    T659I Details
    V665I Details
    A669V Natural polymorphism Details
    A674T 8-cyclopentyl-1,3-dipropylxanthine 0.91 No resistance Details Characterization of human cytomegalovirus (HCMV) UL97 mutations found in a valganciclovir/oral ganciclovir prophylactic trial by use of a bacterial artificial chromosome containing the HCMV genome. (Sep 2006)